The Bridging Antiplatelet Therapy With Cangrelor 2 Study

Summary

The primary aim of this study is to determine rates of patients with optimal platelet reactivity range, defined as PRU levels between 85 and 208, when using a (PFT)-guided titration of cangrelor infusion rate (cangrelor titration) compared to 0.75 mcg/kg/min (standard-dose infusion) for bridging.

Eligibility

Inclusion Criteria:

1. Any patient receiving bridging with standard-dose cangrelor infusion rate of 0.75 mcg/Kg/min for at least two hours as part of their standard of care.
2. Age ≥18 years
3. Provide written informed consent.

Exclusion Criteria:

1. Need for urgent surgery
2. Confirmed or suspected pregnancy (in woman of child-bearing potential) or lactating females
3. Exposure to any oral P2Y12 inhibitor, oral anticoagulant or glycoprotein IIb/IIIa inhibitor within 48 hours.
4. Known allergy, and hypersensitivity, or contraindication to cangrelor, mannitol, sorbitol, or microcrystalline cellulose

Conditions2

Interventions1

Locations1 site

Find trials near these locations

Related trials

• Cangrelor on Top of anticoagUlation in Patients With myocaRdial Infarction-related Cardiogenic Shock/Cardiac Arrest receiVIng VA-ECMO — IRCCS San Raffaele

Browse More Trials